Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 63

Similar articles for PubMed (Select 17893943)

1.

Collagen-targeted MRI contrast agent for molecular imaging of fibrosis.

Caravan P, Das B, Dumas S, Epstein FH, Helm PA, Jacques V, Koerner S, Kolodziej A, Shen L, Sun WC, Zhang Z.

Angew Chem Int Ed Engl. 2007;46(43):8171-3. No abstract available.

PMID:
17893943
2.

The binding of CNA35 contrast agents to collagen fibrils.

Sanders HM, Iafisco M, Pouget EM, Bomans PH, Nudelman F, Falini G, de With G, Merkx M, Strijkers GJ, Nicolay K, Sommerdijk NA.

Chem Commun (Camb). 2011 Feb 7;47(5):1503-5. doi: 10.1039/c0cc02901g. Epub 2010 Nov 18.

PMID:
21088778
3.

Using two chemical exchange saturation transfer magnetic resonance imaging contrast agents for molecular imaging studies.

Ali MM, Liu G, Shah T, Flask CA, Pagel MD.

Acc Chem Res. 2009 Jul 21;42(7):915-24. doi: 10.1021/ar8002738.

PMID:
19514717
4.

Molecular magnetic resonance imaging of myocardial perfusion with EP-3600, a collagen-specific contrast agent: initial feasibility study in a swine model.

Spuentrup E, Ruhl KM, Botnar RM, Wiethoff AJ, Buhl A, Jacques V, Greenfield MT, Krombach GA, G√ľnther RW, Vangel MG, Caravan P.

Circulation. 2009 Apr 7;119(13):1768-75. doi: 10.1161/CIRCULATIONAHA.108.826388. Epub 2009 Mar 23.

5.

Morphology, binding behavior and MR-properties of paramagnetic collagen-binding liposomes.

Sanders HM, Strijkers GJ, Mulder WJ, Huinink HP, Erich SJ, Adan OC, Sommerdijk NA, Merkx M, Nicolay K.

Contrast Media Mol Imaging. 2009 Mar-Apr;4(2):81-8. doi: 10.1002/cmmi.266.

PMID:
19191276
7.

Preparation and in vivo imaging of PEG-poly(L-lysine)-based polymeric micelle MRI contrast agents.

Shiraishi K, Kawano K, Minowa T, Maitani Y, Yokoyama M.

J Control Release. 2009 May 21;136(1):14-20. doi: 10.1016/j.jconrel.2009.01.010. Epub 2009 Jan 23.

PMID:
19331861
8.

Linear assemblies of magnetic nanoparticles as MRI contrast agents.

Corr SA, Byrne SJ, Tekoriute R, Meledandri CJ, Brougham DF, Lynch M, Kerskens C, O'Dwyer L, Gun'ko YK.

J Am Chem Soc. 2008 Apr 2;130(13):4214-5. doi: 10.1021/ja710172z. Epub 2008 Mar 11.

PMID:
18331033
9.

Gd-DOTA conjugate of RGD as a potential tumor-targeting MRI contrast agent.

Park JA, Lee JJ, Jung JC, Yu DY, Oh C, Ha S, Kim TJ, Chang Y.

Chembiochem. 2008 Nov 24;9(17):2811-3. doi: 10.1002/cbic.200800529. No abstract available.

PMID:
18956393
10.

Study of manganese bacteriopheophorbide as a potential contrast agent for magnetic resonance tomography.

Meerovich IG, Brandis A, Meerovich GA, Stratonnikov AA, Bendel P, Oborotova NA, Shertz A, Baryshnikov AY.

Bull Exp Biol Med. 2007 Apr;143(4):452-4.

PMID:
18214298
11.

Dynamic imaging of lymphatic vessels and lymph nodes using a bimodal nanoparticulate contrast agent.

Mounzer R, Shkarin P, Papademetris X, Constable T, Ruddle NH, Fahmy TM.

Lymphat Res Biol. 2007;5(3):151-8.

PMID:
18035933
12.

A novel cholic acid-based contrast enhancement agent for targeted MRI.

Chong HS, Song HA, Lim S, Macrenaris K, Ma X, Lee H, Bui P, Meade T.

Bioorg Med Chem Lett. 2008 Apr 1;18(7):2505-8. doi: 10.1016/j.bmcl.2008.01.044. Epub 2008 Jan 18.

PMID:
18337094
13.

Pushing the sensitivity envelope of lanthanide-based magnetic resonance imaging (MRI) contrast agents for molecular imaging applications.

Aime S, Castelli DD, Crich SG, Gianolio E, Terreno E.

Acc Chem Res. 2009 Jul 21;42(7):822-31. doi: 10.1021/ar800192p. Review.

PMID:
19534516
14.

An ApoA-I mimetic peptide high-density-lipoprotein-based MRI contrast agent for atherosclerotic plaque composition detection.

Cormode DP, Briley-Saebo KC, Mulder WJ, Aguinaldo JG, Barazza A, Ma Y, Fisher EA, Fayad ZA.

Small. 2008 Sep;4(9):1437-44. doi: 10.1002/smll.200701285.

PMID:
18712752
15.

Surface functionalization of single superparamagnetic iron oxide nanoparticles for targeted magnetic resonance imaging.

Amstad E, Zurcher S, Mashaghi A, Wong JY, Textor M, Reimhult E.

Small. 2009 Jun;5(11):1334-42. doi: 10.1002/smll.200801328.

PMID:
19242944
16.

A lysine walk to high relaxivity collagen-targeted MRI contrast agents.

Caravan P, Das B, Deng Q, Dumas S, Jacques V, Koerner SK, Kolodziej A, Looby RJ, Sun WC, Zhang Z.

Chem Commun (Camb). 2009 Jan 28;(4):430-2. doi: 10.1039/b819098d. Epub 2008 Dec 10.

PMID:
19137175
17.

Comparison of supine magnetic resonance imaging with and without rectal contrast to fluoroscopic cystocolpoproctography for the diagnosis of pelvic organ prolapse.

Pannu HK, Scatarige JC, Eng J.

J Comput Assist Tomogr. 2009 Jan-Feb;33(1):125-30. doi: 10.1097/RCT.0b013e318161d739.

PMID:
19188799
18.

Dynamic contrast enhanced MRI of mouse fibrosarcoma using small-molecular and novel macromolecular contrast agents.

Ivanusa T, Beravs K, Medic J, Sersa I, Sersa G, Jevtic V, Demsar F, Mikac U.

Phys Med. 2007 Dec;23(3-4):85-90. Epub 2007 Jul 9.

PMID:
18061121
19.

Mesoporous silica nanospheres as highly efficient MRI contrast agents.

Taylor KM, Kim JS, Rieter WJ, An H, Lin W, Lin W.

J Am Chem Soc. 2008 Feb 20;130(7):2154-5. doi: 10.1021/ja710193c. Epub 2008 Jan 25. No abstract available.

PMID:
18217764
20.

Molecular coronary MR imaging of human thrombi using EP-2104R, a fibrin-targeted contrast agent: experimental study in a swine model.

Spuentrup E, Katoh M, Wiethoff AJ, Buecker A, Botnar RM, Parsons EC, Guenther RW.

Rofo. 2007 Nov;179(11):1166-73.

PMID:
17948194
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk